Oct. 07--If we were to present her research as an action movie plot, this is how
Kate Rittenhouse-Olson and her team at the University at Buffalo plan to beat
A SWAT team of engineered antibodies hunts down cancer tumors where they live,
secures the perimeter so they can't escape and then busts down the door and
delivers a fatal dose of chemicals to finish the job, with no civilian
In a few years, this show could be playing in patients everywhere.
The most difficult part -- that of the antibodies -- is already filled. They
were discovered -- actually created -- by Rittenhouse-Olson in her lab nearly 20
years ago, by cloning a mouse spleen cell with a mouse tumor cell.
"It got its immortality from the tumor cell and the antibody from the mouse
spleen cell," she explains, keeping it simple.
She named the new antibody JAA-F11. That sounds like a fighter jet that shoots
down tumors, but this microbiologist is more sentimental. She made the name from
the initials of her three children, Jennifer, Anna and Andrew, combined with the
grid location -- F11 -- in the culture plate where the antibody grew.
After her initial discovery, she has worked with students and her longtime
research lab technician Susan Morey to reproduce the antibody and test its
ability to stop cancer in its tracks, using mice as live subjects and human
cells in Petri dishes. Now, they are "humanizing" the antibody, taking the mouse
antibody binding ability and attaching it to human antibody molecules.
JAA-F11 bonds with the part of the cancer cell -- a sugar, the
Thomsen-Friedenreich antigen -- that helps it move through the bloodstream. Once
JAA-F11 attaches, the antigen doesn't work and the cancer doesn't spread.
It has proven to be remarkably effective.
Now, JAA-F11 is taking its first major steps in front of a wider audience.
Rittenhouse-Olson has started a company to develop a marketable cancer therapy
and already has early interest from several major pharmaceutical companies.
She has been awarded hundreds of thousands of dollars from the National Cancer
Institute and University at Buffalo to begin the next phase of testing on her
breakthrough, which is a few steps ahead of human trials.
"We aren't all the way there, but it shows real promise," Rittenhouse-Olson
(c)2013 The Buffalo News (Buffalo, N.Y.)
Visit The Buffalo News (Buffalo, N.Y.) at www.buffalonews.com
Distributed by MCT Information Services